Published in J Cancer Res Clin Oncol on January 29, 2004
Urine biomarkers in prostate cancer. Nat Rev Urol (2010) 1.17
Markers for detection of prostate cancer. Cancers (Basel) (2010) 0.82
Urine chemokines indicate pathogenic association of obesity with BPH/LUTS. Int Urol Nephrol (2015) 0.75
Effects of 5 alpha reductase inhibitors on androgen-dependent human prostatic carcinoma cells. J Cancer Res Clin Oncol (2005) 0.75
Specific association of human telomerase activity with immortal cells and cancer. Science (1994) 28.20
Structure and function of telomeres. Nature (1991) 14.82
A survey of telomerase activity in human cancer. Eur J Cancer (1997) 10.84
Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med (1991) 6.94
Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer. J Urol (1993) 1.91
Telomerase activity: a prevalent marker of malignant human prostate tissue. Cancer Res (1996) 1.87
The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population. J Urol (1997) 1.67
Telomerase is a highly sensitive and specific molecular marker in fine-needle aspirates of breast lesions. J Clin Oncol (1999) 1.43
Telomerase activity is detected in pancreatic cancer but not in benign tumors. Cancer Res (1997) 1.34
Alternative lengthening of telomeres is associated with chromosomal instability in osteosarcomas. Oncogene (2001) 1.29
Telomere maintenance and cancer -- look, no telomerase. Nat Rev Cancer (2002) 1.17
Telomerase activity in prostate cancer, prostatic intraepithelial neoplasia, and benign prostatic epithelium. Cancer Res (1998) 0.94
Increased sensitivity and reproducibility of TRAP assay by avoiding direct primers interaction. Nucleic Acids Res (1998) 0.87
Detection of telomerase activity in human prostate: a diagnostic marker for prostatic cancer? Br J Urol (1997) 0.87
The use of telomerase activity for the detection of prostatic cancer cells after prostatic massage. J Urol (2001) 0.83
Telomerase activity in pleural effusions: diagnostic significance. J Clin Oncol (1998) 0.81
Telomere lengthening in telomerase-negative cells: the ends are coming together. Virchows Arch (2002) 0.81
Early diagnosis of prostatic carcinoma based on in vitro culture of viable tumor cells harvested by prostatic massage. Eur Urol (1988) 0.80
Does free to total ratio of prostate-specific antigen alter decision-making on prostatic biopsy? Urology (1996) 0.76
Detection of telomerase activity in prostatic fluid specimens. Urol Oncol (2000) 0.76
Improved tissue culture method for the study of prostatic carcinoma: a significant diagnostic tool. Pathol Res Pract (1995) 0.75
Early diagnosis of prostatic carcinoma may be achieved through in vitro culture of tumor cells harvested by prostatic massage. Eur Urol (1993) 0.75
An appraisal of telomerase activity in benign prostatic hyperplasia. Prostate (2000) 0.75
Is there evidence of a relationship between benign prostatic hyperplasia and prostate cancer? Findings of a literature review. Eur Urol (2008) 2.65
The prevalence of lower urinary tract symptoms (LUTS) in the USA, the UK and Sweden: results from the Epidemiology of LUTS (EpiLUTS) study. BJU Int (2009) 2.63
Bipolar transurethral resection of prostate: clinical and urodynamic evaluation. Urology (2008) 2.20
The number of cores positive for high grade prostatic intraepithelial neoplasia on initial biopsy is associated with prostate cancer on second biopsy. J Urol (2009) 2.14
EAU guidelines on urinary incontinence. Eur Urol (2010) 2.10
Assessing the accuracy and generalizability of the preoperative and postoperative Karakiewicz nomograms for renal cell carcinoma: results from a multicentre European and US study. BJU Int (2013) 2.08
EAU guidelines on surgical treatment of urinary incontinence. Eur Urol (2012) 2.05
Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice. Endocr Relat Cancer (2006) 2.04
The burden of lower urinary tract symptoms: evaluating the effect of LUTS on health-related quality of life, anxiety and depression: EpiLUTS. BJU Int (2009) 2.00
A contemporary assessment of nocturia: definition, epidemiology, pathophysiology, and management--a systematic review and meta-analysis. Eur Urol (2012) 1.81
Metabolic syndrome and benign prostatic enlargement: a systematic review and meta-analysis. BJU Int (2014) 1.73
The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol (2011) 1.71
Ultrasound estimated bladder weight and measurement of bladder wall thickness--useful noninvasive methods for assessing the lower urinary tract? J Urol (2010) 1.67
The impact of obesity on the predictive accuracy of PSA in men undergoing prostate biopsy. World J Urol (2012) 1.51
The influence of family history on prostate cancer risk: implications for clinical management. BJU Int (2010) 1.48
Validity of the international consultation on incontinence questionnaire-pediatric lower urinary tract symptoms: a screening questionnaire for children. J Urol (2010) 1.48
Salvage laparoscopic radical prostatectomy following high-intensity focused ultrasound for treatment of prostate cancer. Urology (2012) 1.46
Kinase-dependent and -independent roles of EphA2 in the regulation of prostate cancer invasion and metastasis. Am J Pathol (2009) 1.46
Systematic review and meta-analysis of randomized controlled trials evaluating silodosin in the treatment of non-neurogenic male lower urinary tract symptoms suggestive of benign prostatic enlargement. World J Urol (2012) 1.43
Greater percent-free testosterone is associated with high-grade prostate cancer in men undergoing prostate biopsy. Urology (2012) 1.43
The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTS. BJU Int (2009) 1.40
Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder. Eur Urol (2007) 1.40
Photoselective prostatic vaporization for bladder outlet obstruction: 12-month evaluation of storage and voiding symptoms. J Urol (2010) 1.38
Development and validation of patient-reported outcomes measures for overactive bladder: a review of concepts. Urology (2006) 1.35
Benign prostatic hyperplasia: a progressive disease of aging men. Urology (2003) 1.31
Inhibition of protein kinase c-Src reduces the incidence of breast cancer metastases and increases survival in mice: implications for therapy. J Pharmacol Exp Ther (2006) 1.26
Chordoma of the skull base: predictors of tumor recurrence. J Neurosurg (2003) 1.24
EAU guidelines on assessment and nonsurgical management of urinary incontinence. Eur Urol (2012) 1.23
Nucleo-cytoplasmic transport as a therapeutic target of cancer. J Hematol Oncol (2014) 1.19
Translating overactive bladder questionnaires in 14 languages. Urology (2006) 1.17
Biological rationale for the use of DNA methyltransferase inhibitors as new strategy for modulation of tumor response to chemotherapy and radiation. Mol Cancer (2010) 1.16
Transmission of information between complex systems: 1/f resonance. Phys Rev E Stat Nonlin Soft Matter Phys (2011) 1.09
Fat boosts, while androgen receptor activation counteracts, BPH-associated prostate inflammation. Prostate (2012) 1.07
Treatment options for benign prostatic hyperplasia in older men. Med Sci Monit (2008) 1.07
EphA2 induces metastatic growth regulating amoeboid motility and clonogenic potential in prostate carcinoma cells. Mol Cancer Res (2011) 1.06
Inhibition of interleukin-8 (CXCL8/IL-8) responses by repertaxin, a new inhibitor of the chemokine receptors CXCR1 and CXCR2. Biochem Pharmacol (2004) 1.06
The role of antimuscarinics in the management of men with symptoms of overactive bladder associated with concomitant bladder outlet obstruction: an update. Eur Urol (2011) 1.05
MEK/ERK inhibitor U0126 increases the radiosensitivity of rhabdomyosarcoma cells in vitro and in vivo by downregulating growth and DNA repair signals. Mol Cancer Ther (2011) 1.05
Tyrosine kinase inhibitor CEP-701 blocks the NTRK1/NGF receptor and limits the invasive capability of prostate cancer cells in vitro. Int J Oncol (2007) 1.03
An overview of the effect of linoleic and conjugated-linoleic acids on the growth of several human tumor cell lines. Int J Cancer (2004) 1.03
Tamsulosin treatment increases clinical success rate of single extracorporeal shock wave lithotripsy of renal stones. Urology (2005) 1.01
Variability of detrusor overactivity on repeated filling cystometry in men with urge symptoms: comparison with spinal cord injury patients. BJU Int (2005) 1.01
XPO1/CRM1-selective inhibitors of nuclear export (SINE) reduce tumor spreading and improve overall survival in preclinical models of prostate cancer (PCa). J Hematol Oncol (2014) 0.99
Metabolic syndrome is associated with high grade Gleason score when prostate cancer is diagnosed on biopsy. Prostate (2011) 0.98
Overactive bladder: Is there a link to the metabolic syndrome in men? Neurourol Urodyn (2010) 0.98
Mechanisms of continence and surgical cure in female and male SUI: surgical research initiatives. Neurourol Urodyn (2011) 0.96
Serum prostate-specific antigen to predict the presence of bladder outlet obstruction in men with urinary symptoms. BJU Int (2004) 0.95
Azacitidine improves antitumor effects of docetaxel and cisplatin in aggressive prostate cancer models. Endocr Relat Cancer (2009) 0.95
Antisense oligodeoxynucleotides for urokinase-plasminogen activator receptor have anti-invasive and anti-proliferative effects in vitro and inhibit spontaneous metastases of human melanoma in mice. Int J Cancer (2004) 0.95
Gender differences in clinicopathological features and survival in surgically treated patients with renal cell carcinoma: an analysis of the multicenter CORONA database. World J Urol (2013) 0.94
Osteopontin enhances the cell proliferation induced by the epidermal growth factor in human prostate cancer cells. Prostate (2004) 0.94
Fluctuation-dissipation theorem for event-dominated processes. Phys Rev Lett (2007) 0.94
Ultrasound assessment of intravesical prostatic protrusion and detrusor wall thickness--new standards for noninvasive bladder outlet obstruction diagnosis? J Urol (2010) 0.94
Epidermal growth factor modulates prostate cancer cell invasiveness regulating urokinase-type plasminogen activator activity. EGF-receptor inhibition may prevent tumor cell dissemination. Thromb Haemost (2005) 0.93
Reporting quality of abstracts presented at the European Association of Urology meeting: a critical assessment. J Urol (2012) 0.92
Receptor activator of NF-kappaB ligand enhances breast cancer-induced osteolytic lesions through upregulation of extracellular matrix metalloproteinase inducer/CD147. Cancer Res (2010) 0.92
Hormonal therapy promotes hormone-resistant phenotype by increasing DNMT activity and expression in prostate cancer models. Endocrinology (2011) 0.92
Torc1/Torc2 inhibitor, Palomid 529, enhances radiation response modulating CRM1-mediated survivin function and delaying DNA repair in prostate cancer models. Prostate (2014) 0.92
Toll-like receptor 3 (TLR3) activation induces microRNA-dependent reexpression of functional RARβ and tumor regression. Proc Natl Acad Sci U S A (2013) 0.92
May antioxidant therapy improve sperm parameters of men with persistent oligospermia after retrograde embolization for varicocele? World J Urol (2007) 0.91
Valproic acid induces apoptosis in prostate carcinoma cell lines by activation of multiple death pathways. Anticancer Drugs (2006) 0.91
Granzyme B is expressed in urothelial carcinoma and promotes cancer cell invasion. Int J Cancer (2010) 0.91
Assessment of dose exposure and image quality in coronary angiography performed by 640-slice CT: a comparison between adaptive iterative and filtered back-projection algorithm by propensity analysis. Radiol Med (2014) 0.91
Clinically overt venous thromboembolism after urologic cancer surgery: results from the @RISTOS Study. Eur Urol (2006) 0.90
Impact of fesoterodine on quality of life: pooled data from two randomized trials. BJU Int (2008) 0.90
Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures. J Cancer Res Clin Oncol (2003) 0.90
Differential effects of PXD101 (belinostat) on androgen-dependent and androgen-independent prostate cancer models. Int J Oncol (2011) 0.90
Type 5 phosphodiesterase expression in the human vagina. Urology (2002) 0.89
Bicalutamide increases phospho-Akt levels through Her2 in patients with prostate cancer. Endocr Relat Cancer (2007) 0.89
The VIOXX in Prostate Cancer Prevention study: cardiovascular events observed in the rofecoxib 25 mg and placebo treatment groups. Curr Med Res Opin (2007) 0.89
Akt down-modulation induces apoptosis of human prostate cancer cells and synergizes with EGFR tyrosine kinase inhibitors. Prostate (2008) 0.89
Additive antitumor effects of the epidermal growth factor receptor tyrosine kinase inhibitor, gefitinib (Iressa), and the nonsteroidal antiandrogen, bicalutamide (Casodex), in prostate cancer cells in vitro. Int J Cancer (2005) 0.89
Experimental quenching of harmonic stimuli: universality of linear response theory. Phys Rev Lett (2009) 0.89
The impact of lower urinary tract symptoms on male sexual health: EpiLUTS. BJU Int (2009) 0.89